Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/21
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 08/04/21
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/30/21
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)GlobeNewsWire • 07/25/21
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021GlobeNewsWire • 07/15/21
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) PatientsGlobeNewsWire • 06/28/21
Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?Zacks Investment Research • 06/02/21
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising InvestmentSeeking Alpha • 06/02/21
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/03/21
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 05/03/21
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 EndBenzinga • 05/03/21
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson's DiseaseGlobeNewsWire • 05/01/21
Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/21
5 Sizzling Stocks to Buy Now as the Russell 2000 Continues to Explode Higher24/7 Wall Street • 03/22/21
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)GlobeNewsWire • 03/11/21
Denali Therapeutics Reports Full Year 2020 Financial Results and Business HighlightsGlobeNewsWire • 02/25/21
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular TargetPRNewsWire • 02/25/21